Trial Profile
A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epogen®/Procrit® when given subcutaneously to patients with anemia and chronic kidney disease not yet on hemodialysis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Apotex
- 25 Jan 2018 New trial record